The Effect of Sunitinib Treatment in Human Melanoma Xenografts: Associations with Angiogenic Profiles

The effect of antiangiogenic agents targeting the vascular endothelial growth factor A (VEGF-A) pathway has been reported to vary substantially in preclinical studies. The purpose of this study was to investigate the effect of sunitinib treatment on tumor vasculature and oxygenation in melanoma xeno...

Full description

Bibliographic Details
Main Authors: Jon-Vidar Gaustad, Trude G. Simonsen, Lise Mari K. Andersen, Einar K. Rofstad
Format: Article
Language:English
Published: Elsevier 2017-04-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523316302212
_version_ 1818508140621070336
author Jon-Vidar Gaustad
Trude G. Simonsen
Lise Mari K. Andersen
Einar K. Rofstad
author_facet Jon-Vidar Gaustad
Trude G. Simonsen
Lise Mari K. Andersen
Einar K. Rofstad
author_sort Jon-Vidar Gaustad
collection DOAJ
description The effect of antiangiogenic agents targeting the vascular endothelial growth factor A (VEGF-A) pathway has been reported to vary substantially in preclinical studies. The purpose of this study was to investigate the effect of sunitinib treatment on tumor vasculature and oxygenation in melanoma xenografts with different angiogenic profiles. A-07, U-25, D-12, or R-18 melanoma xenografts were grown in dorsal window chambers and given daily treatments of sunitinib (40 mg/kg) or vehicle. Morphologic parameters of tumor vascular networks were assessed from high-resolution transillumination images, and tumor blood supply times (BSTs) were assessed from first-pass imaging movies. Tumor hypoxia was assessed with immunohistochemistry by using pimonidazole as hypoxia marker, and the gene expression and the protein secretion rate of angiogenic factors were assessed by quantitative polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. The melanoma lines differed substantially in the expression of VEGF-A, VEGF-C, and platelet-derived growth factor A. Sunitinib treatment reduced vessel densities and induced hypoxia in all melanoma lines, and the magnitude of the effect was associated with the gene expression and protein secretion rate of VEGF-A. Sunitinib treatment also increased vessel segment lengths, reduced the number of small-diameter vessels, and inhibited growth-induced increases in the diameter of surviving vessels but did not change BST. In conclusion, sunitinib treatment did not improve vascular function but reduced vessel density and induced hypoxia in human melanoma xenografts. The magnitude of the treatment-induced effect was associated with the VEGF-A expression of the melanoma lines.
first_indexed 2024-12-10T22:27:39Z
format Article
id doaj.art-e666aa00b7ff4c43aa10f86e0bc9fb07
institution Directory Open Access Journal
issn 1936-5233
1944-7124
language English
last_indexed 2024-12-10T22:27:39Z
publishDate 2017-04-01
publisher Elsevier
record_format Article
series Translational Oncology
spelling doaj.art-e666aa00b7ff4c43aa10f86e0bc9fb072022-12-22T01:31:08ZengElsevierTranslational Oncology1936-52331944-71242017-04-0110215816710.1016/j.tranon.2016.12.007The Effect of Sunitinib Treatment in Human Melanoma Xenografts: Associations with Angiogenic ProfilesJon-Vidar GaustadTrude G. SimonsenLise Mari K. AndersenEinar K. RofstadThe effect of antiangiogenic agents targeting the vascular endothelial growth factor A (VEGF-A) pathway has been reported to vary substantially in preclinical studies. The purpose of this study was to investigate the effect of sunitinib treatment on tumor vasculature and oxygenation in melanoma xenografts with different angiogenic profiles. A-07, U-25, D-12, or R-18 melanoma xenografts were grown in dorsal window chambers and given daily treatments of sunitinib (40 mg/kg) or vehicle. Morphologic parameters of tumor vascular networks were assessed from high-resolution transillumination images, and tumor blood supply times (BSTs) were assessed from first-pass imaging movies. Tumor hypoxia was assessed with immunohistochemistry by using pimonidazole as hypoxia marker, and the gene expression and the protein secretion rate of angiogenic factors were assessed by quantitative polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. The melanoma lines differed substantially in the expression of VEGF-A, VEGF-C, and platelet-derived growth factor A. Sunitinib treatment reduced vessel densities and induced hypoxia in all melanoma lines, and the magnitude of the effect was associated with the gene expression and protein secretion rate of VEGF-A. Sunitinib treatment also increased vessel segment lengths, reduced the number of small-diameter vessels, and inhibited growth-induced increases in the diameter of surviving vessels but did not change BST. In conclusion, sunitinib treatment did not improve vascular function but reduced vessel density and induced hypoxia in human melanoma xenografts. The magnitude of the treatment-induced effect was associated with the VEGF-A expression of the melanoma lines.http://www.sciencedirect.com/science/article/pii/S1936523316302212
spellingShingle Jon-Vidar Gaustad
Trude G. Simonsen
Lise Mari K. Andersen
Einar K. Rofstad
The Effect of Sunitinib Treatment in Human Melanoma Xenografts: Associations with Angiogenic Profiles
Translational Oncology
title The Effect of Sunitinib Treatment in Human Melanoma Xenografts: Associations with Angiogenic Profiles
title_full The Effect of Sunitinib Treatment in Human Melanoma Xenografts: Associations with Angiogenic Profiles
title_fullStr The Effect of Sunitinib Treatment in Human Melanoma Xenografts: Associations with Angiogenic Profiles
title_full_unstemmed The Effect of Sunitinib Treatment in Human Melanoma Xenografts: Associations with Angiogenic Profiles
title_short The Effect of Sunitinib Treatment in Human Melanoma Xenografts: Associations with Angiogenic Profiles
title_sort effect of sunitinib treatment in human melanoma xenografts associations with angiogenic profiles
url http://www.sciencedirect.com/science/article/pii/S1936523316302212
work_keys_str_mv AT jonvidargaustad theeffectofsunitinibtreatmentinhumanmelanomaxenograftsassociationswithangiogenicprofiles
AT trudegsimonsen theeffectofsunitinibtreatmentinhumanmelanomaxenograftsassociationswithangiogenicprofiles
AT lisemarikandersen theeffectofsunitinibtreatmentinhumanmelanomaxenograftsassociationswithangiogenicprofiles
AT einarkrofstad theeffectofsunitinibtreatmentinhumanmelanomaxenograftsassociationswithangiogenicprofiles
AT jonvidargaustad effectofsunitinibtreatmentinhumanmelanomaxenograftsassociationswithangiogenicprofiles
AT trudegsimonsen effectofsunitinibtreatmentinhumanmelanomaxenograftsassociationswithangiogenicprofiles
AT lisemarikandersen effectofsunitinibtreatmentinhumanmelanomaxenograftsassociationswithangiogenicprofiles
AT einarkrofstad effectofsunitinibtreatmentinhumanmelanomaxenograftsassociationswithangiogenicprofiles